Barasertib

Barasertib

SCHEMBL29368256

CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(=O)(O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

AURKB

The experimentally established mechanism targets of Barasertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AURKB known ✓ Q96GD4 13/20 1.00
AURKA O14965 17/20 1.00
EGFR P00533 4/20 1.00
KDR P35968 4/20 1.00
RIPK2 O43353 2/20 1.00
LCK P06239 2/20 1.00
LYN P07948 2/20 1.00
RET P07949 2/20 1.00
HCK P08631 2/20 1.00
PDGFRB P09619 2/20 1.00
KIT P10721 2/20 1.00
PDGFRA P16234 2/20 1.00
CSNK2A2 P19784 2/20 1.00
FLT3 P36888 2/20 1.00
MST1R Q04912 2/20 1.00
MAP2K5 Q13163 2/20 1.00
AURKC Q9UQB9 2/20 1.00
MAP4K5 Q9Y4K4 2/20 1.00
FYN P06241 1/20 1.00
RAB6A P20340 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Barasertib SCHEMBL29720420 1.00 AURKA (1.00) AURKAAURKBEGFRKDRRIPK2
Barasertib SCHEMBL613582 1.00 AURKA (1.00) AURKAAURKBEGFRKDRRIPK2
SCHEMBL3490131 0.98 AURKA (0.96) AURKAAURKBEGFRKDRRIPK2
SCHEMBL4275319 0.97 AURKA (0.94) AURKAAURKBEGFRKDRRIPK2
SCHEMBL3489414 0.96 AURKA (0.93) AURKAAURKBEGFRKDRRIPK2
SCHEMBL12132713 0.95 AURKA (0.92) AURKAAURKBEGFRKDRRIPK2
SCHEMBL613581 0.95 AURKA (0.91) AURKAAURKBEGFRKDRRIPK2
SCHEMBL3862878 0.95 AURKA (0.90) AURKAAURKBEGFRKDRRIPK2
SCHEMBL3489712 0.95 AURKA (0.90) AURKAAURKBEGFRKDRRIPK2
SCHEMBL12132714 0.95 AURKA (0.90) AURKAAURKBEGFRKDRRIPK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2193 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12577255-B2 MDM2-based modulators of proteolysis and associated methods of use ARVINAS OPERATIONS, INC. (US) 2026-03-17 US claimed
EP-4048260-B1 COMBINATION OF SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING A HEMATOLOGICAL MALIGNANCY CELGENE CORP (US) 2026-03-11 EP claimed
EP-4704832-A2 BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS Biohaven Therapeutics Ltd. (VG) 2026-03-11 EP claimed
US-12533353-B2 Methods of treatment of cancer comprising CDC7 inhibitors CARNA BIOSCIENCES, INC. (JP) 2026-01-27 US claimed
US-20260022117-A1 COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS ARVINAS OPERATIONS INC (US) 2026-01-22 US claimed
US-12485178-B2 Bifunctional small molecules to target the selective degradation of circulating proteins YALE UNIVERSITY (US) 2025-12-02 US claimed
US-20250352551-A1 SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE CELGENE CORPORATION 2025-11-20 US claimed
US-20250332274-A1 BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS UNIV YALE (US) 2025-10-30 US claimed
EP-4637832-A1 CONJUGATES COMPRISING A PHOSPHORUS(V) MOIETY AND A DRUG Tubulis GmbH (DE) 2025-10-29 EP claimed
WO-2025215042-A1 COMBINATIONS OF A CALCIUM HOMEOSTASIS DISRUPTOR WITH A DEATH RECEPTOR 5 AGONIST FOR TREATING CANCER STICHTING HET NEDERLANDS KANKER INSTITUUT - ANTONI VAN LEEUWENHOEK ZIEKENHUIS (NL) 2025-10-16 WO claimed
US-20220244263-A1 METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-08-04 US claimed
EP-4031543-A1 BIAMINOQUINOLINES AND NANOFORMULATIONS FOR CANCER TREATMENT THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-07-27 EP claimed
WO-2022154664-A1 INDUCERS OF SENESCENCE, IN COMBINATION WITH A SELECTIVE DEATH RECEPTOR 5 (DR5) AGONIST, FOR USE IN A METHOD OF TREATING CANCER Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis (NL) 2022-07-21 WO claimed
WO-2022144780-A1 SULFONAMIDE DERIVATIVES, COMPOSITIONS COMPRISING SAME AND USES THEREOF IN THE TREATMENT OF CANCERS NATIONAL CANCER CENTER (JP) 2022-07-07 WO claimed
US-11331272-B2 Hyperstabilized liposomes increase targeting of mitotic cells TEMASEK LIFE SCIENCES LABORATORY LIMITED (SG) 2022-05-17 US claimed
WO-2022090746-A1 NMT INHIBITORS FOR TREATING SENESCENCE-ASSOCIATED DISEASES OR DISORDERS IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2022-05-05 WO claimed
EP-3982952-A1 METHODS FOR REDUCING TUMOR PROGRESSION AND FIBROSIS AND INCREASING ADAPTIVE IMMUNITY IN MALIGNANCIES GEORGETOWN UNIVERSITY (US) 2022-04-20 EP claimed
US-11298422-B2 Treating tumors with TTFields and an aurora kinase inhibitor NOVOCURE GMBH (CH) 2022-04-12 US claimed
EP-3976195-A1 METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-04-06 EP claimed
US-20220089570-A1 IMIDE-BASED MODULATORS OF PROTEOLYSIS AND ASSOCIATED METHODS OF USE Arvinas, Inc. 2022-03-24 US claimed